Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06195072 · ClinicalTrials.gov registry record · Phase 2
Platform Clinical Study for Conquering Scleroderma
A Phase 2 study of Scleroderma and Interstitial Lung Disease Due to Systemic Disease, sponsored by Scleroderma Research Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06195072 is a Phase 2 study of Scleroderma and Interstitial Lung Disease Due to Systemic Disease that is actively recruiting participants, run by Scleroderma Research Foundation. The registered enrollment target is 400 participants, roughly in line with the 385-participant average among 23 other Scleroderma trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT06195072, a Phase 2 study of Scleroderma and Interstitial Lung Disease Due to Systemic Disease, is actively recruiting participants, sponsored by Scleroderma Research Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amlitelimab
- DRUG BI 1015550 (Nerandomilast)
Study Locations (20)
California
- Keck School of Medicine at USC Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles (UCLA) Ronald Reagan Medical Center - Los Angeles
- Stanford University Medical Center - Palo Alto
Illinois
- Northwestern University - Chicago
- The University of Chicago Medical Center (UCMC) - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Boston University (BU) - Boston
New York
- Northwell Health - Great Neck
- Hospital for Special Surgery - New York
Alabama
- University of Alabama - Division of Pulmonary and Critical Care Medicine - Birmingham
Connecticut
- Yale University School of Medicine - Epilepsy - New Haven
District of Columbia
- Georgetown University Medical Center - Department of Rheumatology - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06195072
The ClinicalTrials.gov registry entry for NCT06195072 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 385-participant average among 23 other Scleroderma trials with a reported enrollment target. The listed sponsor is Scleroderma Research Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Scleroderma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06195072 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06195072 about?
NCT06195072 is a clinical study titled "Platform Clinical Study for Conquering Scleroderma". The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
What is the current status of trial NCT06195072?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2024-04-15. Estimated completion is 2026-11.
What conditions does trial NCT06195072 study?
This clinical trial studies the following conditions: Scleroderma, Interstitial Lung Disease Due to Systemic Disease.
What interventions are being tested in trial NCT06195072?
The interventions under investigation include: Placebo (DRUG), Amlitelimab (DRUG), BI 1015550 (Nerandomilast) (DRUG).
Who is sponsoring clinical trial NCT06195072?
This trial is sponsored by Scleroderma Research Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06195072 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
RECRUITING · Phase 2
-
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
RECRUITING · Phase 2
-
Psychological Treatments for Scleroderma
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.